UK's Antisoma boosted by cancer research breakthrough
08 April 2002 10:48 [Source: ICIS news]
LONDON (CNI)--Shares in Antisoma rose substantially on the London Stock Exchange (LSE) on Monday after the UK biopharmaceutical company announced that its cancer drug Thioplatin possesses properties distinct from those of other platin drugs and shows promising activity on cisplatin-resistant cells.
The research results were disclosed yesterday at the annual meeting of the American Association for Cancer Research in San Francisco, California.
Shares in Antisoma were up 8.8% at 21.5 pence at about 09:30 hours (08:30 GMT) on the London Stock Exchange (LSE).
Thioplatin was developed by scientists at the German Cancer Research Centre and in-licensed by Antisoma in October last year. It is a tumour-targeted version of a platin, a class of drugs that form the cornerstone of cancer treatments against a wide range of solid tumours, including lung, ovarian and testicular cancers.
Antisoma said that, although effective, the therapeutic dose for current platinum-based drugs is often limited by potentially serious side effects, including damage to the kidneys and small intestine. However, Thioplatin is designed to be more active in the acidic environment found around tumours, targeting and killing cancer cells and leaving healthy cells relatively undamaged, it explained.
Lloyd Kelland, Antisoma’s head of laboratory presented new data showing that Thioplatin was active in three human ovarian carcinoma cell lines with acquired cisplatin-resistance. Kelland also presented the results of work carried out at the US National Cancer Institute, which showed that Thioplatin has a unique cancer cell growth inhibition profile across a 60-human tumour cell line when compared with all other platinum compounds in the databank.
By: Neil Sinclair
+44 20 8652 3214
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
| ICIS news FREE TRIAL |
| Get access to breaking chemical news as it happens. |
| ICIS Global Petrochemical Index (IPEX) |
| ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index |
Related Articles
- 18 Nov 02 11:12 UK's Antisoma boosted by cancer drug alliance with Roche
- 29 Jul 02 11:48 Antisoma shares jump 5% after winning UK patent
- 20 May 02 16:17 Antisoma's Q3 pre-tax loss soars 57% on higher R&D costs
- 22 Feb 02 09:26 Antisoma shares slump on £22m rights issue, higher H1 loss
- 04 Jan 02 09:03 UK's Antisoma boosted by cancer drug deal with Abbott
- 06 Jun 01 11:27 UK's Antisoma hit by 'Theragyn' cancer drug trial setback
- 06 Nov 00 00:00 Cancer drug
Latest News
- 19 Jun 13 05:00 China’s Shandong Xinfa Chemical restarts two PVC lines
- 19 Jun 13 04:57 Taiwan's CPC to run Kaohsiung No 5 cracker at 85% for rest of June
- 19 Jun 13 04:28 Japan's chemical exports grow 17% in May
- 19 Jun 13 04:03 Asia ABS prices firmer on buoyant styrene costs
- 18 Jun 13 23:59 Europe June SAN contracts settle at a rollover to slight rise